BioNTech has agreed to pay $791.5 million to the National Institutes of Health and $467 million to the University of Pennsylvania over royalties related to its COVID-19 vaccine.
The lawsuit by the University of Pennsylvania accused BioNTech of underpaying royalties stemming from a sublicense agreement related to the vaccine's technology.
BioNTech, in partnership with Pfizer, developed the Comirnaty vaccine, which was the first to receive emergency use authorization and subsequent regular approval.
These settlements reflect the ongoing financial considerations and legal agreements that come into play for companies involved in groundbreaking medical innovations like COVID-19 vaccines.
Collection
[
|
...
]